Cita APA

KA, P., A, B., L, P., M, O., S, B., M, G., . . . MG, L. (2023). Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.

Citación estilo Chicago

KA, Papp, et al. Long-term Safety and Efficacy of Risankizumab for the Treatment of Moderate-to-severe Plaque Psoriasis: Interim Analysis of the LIMMitless Open-label Extension Trial Up to 5 years of Follow-up. 2023.

Cita MLA

KA, Papp, et al. Long-term Safety and Efficacy of Risankizumab for the Treatment of Moderate-to-severe Plaque Psoriasis: Interim Analysis of the LIMMitless Open-label Extension Trial Up to 5 years of Follow-up. 2023.